Press release
Fecal Incontinence Therapeutics- Pipeline Analysis 2018
Download the sample report at: https://www.pharmaproff.com/request-sample/1026
Passive incontinence is another type of fecal incontinence in which passing of stools is unknown to the patient. Some of the risk factor associated with fecal incontinence are gastrointestinal disorders, such as diarrhoea, constipation, and hemorrhoids.
Get the detailed analysis at: https://www.pharmaproff.com/report/fecal-incontinence-therapeutics-pipeline-analysis
RDD Pharma Ltd. is in the process of developing RDD-0315 as an alpha-adrenergic receptor agonist for the treatment of fecal incontinence. The company has recently completed a successful Phase 2a study of RDD 0315 in fecal incontinence, which reached the primary endpoint (lowered frequency of incontinence events).
Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1026
• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fecal Incontinence Therapeutics- Pipeline Analysis 2018 here
News-ID: 1750399 • Views: …
More Releases for RDD
Rosai-Dorfman Disease (RDD) Market New Product Development & Latest Trends
Introduction
Rosai-Dorfman Disease (RDD), also known as sinus histiocytosis with massive lymphadenopathy, is a rare histiocytic disorder characterized by an overproduction of histiocytes that accumulate in lymph nodes and extranodal sites. While it is often benign, the disease can be progressive and affect multiple organ systems, creating significant morbidity. Due to its rarity and heterogeneous presentation, RDD has historically been underdiagnosed and undertreated.
Management of RDD has evolved from observation and corticosteroids…
Anal Fissure Treatment Market Future Business Opportunities 2024-2031 | Abvie, N …
The Latest research report on the Anal Fissure Treatment Market 2024 provides a comprehensive analysis of the current market landscape, with forecasts extending to 2031. This study combines qualitative and quantitative insights to highlight significant market developments, challenges, competitive dynamics, and potential opportunities and trends shaping the Anal Fissure Treatment Market. The report covers market size, recent trends, growth projections, market share, and development status. Additionally, it examines government policies,…
Anal Fissure Treatment Market Detailed In New Research Report 2024 | Abvie, Nova …
Coherent Market Insights presents encyclopedic research of the Anal Fissure Treatment Market with holistic insights into significant variables and features driving the future growth of the market. The Market was studied for the projected year 2024-2031 as well as the historical period 2017-2023. The research study provides complete qualitative and quantitative analysis to help shareholders obtain a thorough grasp of the Market and its crucial dynamics.
In accordance with coherent market…
Rosai-Dorfman Disease (RDD) Therapeutics Market - Empowering Patients, Defying R …
Newark, New Castle, USA: The "Rosai-Dorfman Disease (RDD) Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Rosai-Dorfman Disease (RDD) Therapeutics Market: https://www.growthplusreports.com/report/rosaidorfman-disease-rdd-therapeutics-market/8943
This latest report researches the…
Rosai-Dorfman Disease (RDD) Therapeutics Market Size, Analysis, Share, Research, …
Newark, New Castle, USA - Growth Plus Reports has published a new report on Rosai-Dorfman Disease (RDD) Therapeutics Market, which includes a detailed analysis based on competitors and important market segments (2023-2031). The Global Rosai-Dorfman Disease (RDD) Therapeutics provides a thorough analysis of many segments such as opportunities, market size, developments, innovation, sales, and overall growth of leading players. The research is based on primary and secondary statistical data, and…
Global Anal Fissure Treatment Market 2020:Competitive Analysis By Teva Pharmaceu …
Global anal fissure treatment market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market.
Data Bridge Market Research recently published a market study on the anal fissure treatment…
